A Study of IBI362 in Participants With Obesity or Overweight

PHASE3CompletedINTERVENTIONAL
Enrollment

610

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

August 21, 2023

Study Completion Date

April 16, 2024

Conditions
Obesity Or Overweight
Interventions
DRUG

Placebo

Placebo administered subcutaneously (SC) once a week.

DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

Trial Locations (23)

100044

People's Hospital of Peking University, Beijing

Unknown

Xuancheng People's Hospital, Xuancheng

Luoyang Third People's Hospital, Luoyang

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

The First Affiliated Hospital of Nanyang Medical University, Nanyang

The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang

Hebei Petro China Central Hospital, Langfang

The First People's Hospital Of Kunshan, Kunshan

Nanjing Drum Tower Hospital, Nanjing

Affiliated Hospital Of Nantong University, Nantong

Suzhou Municipal Hospital, Suzhou

Pingxiang People's Hospital, Pingxiang

China-Japan Union Hospital of Jilin University, Changchun

Shenyang Fifth People's Hospital, Shenyang

Jinan Central Hospital, Ji'nan

Shandong Provincial Third Hospital, Ji'nan

Qilu Hospital Of Shandong University (Qingdao), Qingdao

Tai'an Central Hospital, Tai’an

Zibo Municipal Hospital, Zibo

Shanxi Bethune Hospital, Taiyuan

Yan'an University Xianyang Hospital, Xianyang

Huzhou Central Hospital, Huzhou

Lishui Central Hospital, Lishui

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY